A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY-NIPPON
- Sponsors Sanofi
- 09 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018.